AMPH
Price
$19.29
Change
+$0.57 (+3.04%)
Updated
Jul 13 closing price
Capitalization
850.55M
27 days until earnings call
Intraday BUY SELL Signals
EBS
Price
$8.01
Change
-$0.04 (-0.50%)
Updated
Jul 13 closing price
Capitalization
413.29M
28 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AMPH vs EBS

AMPH vs EBS Comparison Chart in %
View a ticker or compare two or three
VS
AMPH vs. EBS commentary
Jul 14, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMPH is a Hold and EBS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 14, 2026
Stock price -- (AMPH: $19.29 vs. EBS: $8.01)
Brand notoriety: AMPH and EBS are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: AMPH: 35% vs. EBS: 77%
Market capitalization -- AMPH: $850.55M vs. EBS: $413.29M
AMPH [@Pharmaceuticals: Generic] is valued at $850.55M. EBS’s [@Pharmaceuticals: Generic] market capitalization is $413.29M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.97B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMPH’s FA Score shows that 1 FA rating(s) are green whileEBS’s FA Score has 1 green FA rating(s).

  • AMPH’s FA Score: 1 green, 4 red.
  • EBS’s FA Score: 1 green, 4 red.
According to our system of comparison, EBS is a better buy in the long-term than AMPH.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMPH’s TA Score shows that 4 TA indicator(s) are bullish while EBS’s TA Score has 3 bullish TA indicator(s).

  • AMPH’s TA Score: 4 bullish, 5 bearish.
  • EBS’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, AMPH is a better buy in the short-term than EBS.

Price Growth

AMPH (@Pharmaceuticals: Generic) experienced а -1.63% price change this week, while EBS (@Pharmaceuticals: Generic) price change was -2.08% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -3.88%. For the same industry, the average monthly price growth was +0.21%, and the average quarterly price growth was +13.40%.

Reported Earning Dates

AMPH is expected to report earnings on Aug 10, 2026.

EBS is expected to report earnings on Aug 11, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-3.88% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AMPH($851M) has a higher market cap than EBS($413M). AMPH has higher P/E ratio than EBS: AMPH (11.62) vs EBS (8.85). AMPH YTD gains are higher at: -27.969 vs. EBS (-35.194). AMPH has higher annual earnings (EBITDA): 193M vs. EBS (153M). AMPH has more cash in the bank: 292M vs. EBS (160M). EBS has less debt than AMPH: EBS (574M) vs AMPH (686M). AMPH has higher revenues than EBS: AMPH (721M) vs EBS (646M).
AMPHEBSAMPH / EBS
Capitalization851M413M206%
EBITDA193M153M126%
Gain YTD-27.969-35.19479%
P/E Ratio11.628.85131%
Revenue721M646M112%
Total Cash292M160M183%
Total Debt686M574M120%
FUNDAMENTALS RATINGS
AMPH vs EBS: Fundamental Ratings
AMPH
EBS
OUTLOOK RATING
1..100
6459
VALUATION
overvalued / fair valued / undervalued
1..100
60
Fair valued
43
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
7092
PRICE GROWTH RATING
1..100
7561
P/E GROWTH RATING
1..100
206
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EBS's Valuation (43) in the Biotechnology industry is in the same range as AMPH (60) in the Pharmaceuticals Other industry. This means that EBS’s stock grew similarly to AMPH’s over the last 12 months.

EBS's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as AMPH (100) in the Pharmaceuticals Other industry. This means that EBS’s stock grew similarly to AMPH’s over the last 12 months.

AMPH's SMR Rating (70) in the Pharmaceuticals Other industry is in the same range as EBS (92) in the Biotechnology industry. This means that AMPH’s stock grew similarly to EBS’s over the last 12 months.

EBS's Price Growth Rating (61) in the Biotechnology industry is in the same range as AMPH (75) in the Pharmaceuticals Other industry. This means that EBS’s stock grew similarly to AMPH’s over the last 12 months.

EBS's P/E Growth Rating (6) in the Biotechnology industry is in the same range as AMPH (20) in the Pharmaceuticals Other industry. This means that EBS’s stock grew similarly to AMPH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AMPHEBS
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
70%
Bullish Trend 1 day ago
77%
Momentum
ODDS (%)
Bearish Trend 1 day ago
71%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
70%
Bearish Trend 1 day ago
89%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
69%
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
68%
Bullish Trend 1 day ago
82%
Advances
ODDS (%)
Bullish Trend 18 days ago
76%
Bullish Trend 20 days ago
78%
Declines
ODDS (%)
Bearish Trend 12 days ago
70%
Bearish Trend 1 day ago
87%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
71%
N/A
Aroon
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
AMPH
Daily Signal:
Gain/Loss:
EBS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ASRYX8.95N/A
N/A
Invesco Global Real Estate Income Y
QUAYX93.98N/A
N/A
AB Small Cap Growth Advisor
GPROX14.66N/A
N/A
Grandeur Peak Global Reach Inv
VIHAX48.59N/A
N/A
Vanguard Intl Hi Div Yld Adm
AFDZX27.16-0.09
-0.33%
Applied Finance Explorer Institutional

AMPH and

Correlation & Price change

A.I.dvisor indicates that over the last year, AMPH has been loosely correlated with AMRX. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if AMPH jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AMPH
1D Price
Change %
AMPH100%
+3.04%
AMRX - AMPH
50%
Loosely correlated
+1.00%
COLL - AMPH
42%
Loosely correlated
-1.16%
ANIP - AMPH
41%
Loosely correlated
-1.21%
IXHL - AMPH
40%
Loosely correlated
-2.36%
EBS - AMPH
39%
Loosely correlated
-0.50%
More

EBS and

Correlation & Price change

A.I.dvisor indicates that over the last year, EBS has been loosely correlated with SIGA. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if EBS jumps, then SIGA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EBS
1D Price
Change %
EBS100%
-0.50%
SIGA - EBS
41%
Loosely correlated
+0.56%
AMPH - EBS
39%
Loosely correlated
+3.04%
COLL - EBS
36%
Loosely correlated
-1.16%
VTRS - EBS
35%
Loosely correlated
+0.74%
XERS - EBS
33%
Loosely correlated
-2.16%
More